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Abstract  1 
 2 
 A high-throughput method was developed for determination of five 3 
barbiturates (phenobarbital, cyclobarbital, amobarbital, secobarbital, and 4 
thiopental) and a metabolite in human body samples using a new 5 
Monolithic C18 gel-packed Spin Tip and ultra-performance liquid 6 
chromatography (UPLC)-quadrupole-time of flight (Q-ToF) mass 7 
spectrometry (MS). Plasma (20 µl) or urine (100 µl) spiked with the five 8 
barbiturates and 5-(4-methylphenyl)-5-phenylhydantoin (internal standard, 9 
IS) were mixed with distilled water. The mixture was extracted with 10 
Monolithic C18 Spin Tip. The analytes retained on the C18 phase were then 11 
eluted with methanol. The eluate was injected directly into analytical 12 
column (Waters Acquity BEH C18, 50 mm × 2.1 mm i.d., particle size 1.7 13 
µm). Quantification was performed by multiple reaction monitoring with 14 
negative-ion electrospray ionization (ESI). Good separation and clear peak 15 
shapes of the five drugs were achieved within an analysis time of 6 min, 16 
including the extraction time. All drugs spiked in plasma showed 17 
recoveries of 86–98%. The regression equations for the five drugs showed 18 
excellent linearities in the range of 5–500 ng/20 µl of plasma, and the limits 19 
of detection and i-Fit was 1 ng/20 µl. The method was successfully applied 20 
to determine the level of amobarbital and its metabolite in human plasma 21 
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and urine, respectively, after oral administration to a volunteer. This new 1 
method can lead to a wide range of applications in quantitative 2 
determination of drugs and metabolites in the clinical and forensic fields. 3 
 4 
 5 
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Introduction 1 
 2 
Barbiturates are a class of drugs derived from barbituric acid that act as 3 
sedative-hypnotics to the central nervous system [1, 2]. These drugs are 4 
frequently encountered in emergency toxicology screening, drug abuse 5 
testing, and forensic medical examinations [3, 4]. Methods for determining 6 
the concentration of barbiturates in human samples are required for 7 
diagnosis and effective treatment of intoxication and for forensic purposes. 8 
Several methods have been reported for the determination of the levels 9 
of barbiturates in various matrices using gas chromatography [5], gas 10 
chromatography-mass spectrometry [6, 7], high-performance liquid 11 
chromatography (HPLC) [8, 9], and HPLC-mass spectrometry (MS) or 12 
HPLC-tandem MS (MS-MS) [10, 11]. Most of these techniques employ 13 
extraction methods such as liquid-liquid extraction (LLE) [6, 8-10], solid-14 
phase extraction (SPE) [11], or solid-phase microextraction [7] to remove 15 
impurities contained in human body fluid samples. Although LLE and SPE 16 
can successfully extract drugs from biological fluids, these procedures are 17 
generally performed in the off-line mode and are often labor-intensive and 18 
time-consuming.  19 
In this study, we present and discuss new and unique monolithic silica 20 
SPE techniques that use spin tips. An advantage of Monolithic C18 gel-21 
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packed SPE Spin Tip for sample preparation is that extraction can be 1 
carried out more easily and rapidly than with the conventional SPE 2 
cartridges (Fig 1). The small bed volume and sorbent mass within the 3 
monolithic spin tip allow for the use of a reduced solvent volume, smaller 4 
elution volume, reduced time for the extraction step, and higher throughput.  5 
Currently, HPLC-MS/MS mainly based on triple quadrupole instruments, 6 
have been widely applied for the analysis of biological samples [10-17]. 7 
When using HPLC-MS/MS operating in multiple reaction monitoring 8 
(MRM) mode, although quantitative information can be obtained, the 9 
qualitative information needed to support the structural elucidation of 10 
analytes is poor. Recently, HPLC/quadrupole time-of-flight (Q-TOF)-MS 11 
has been used for the unequivocal confirmation of the compounds from 12 
biological and environment samples by accurate mass measurement of 13 
protonated, and deprotonated molecules [18-21]. Accurate mass 14 
measurements of MS/MS product ions have also become particularly 15 
important in the structural elucidation of unknowns. Q-ToF-MS is unique 16 
in its ability to give accurate mass measurements of product ions, assuring 17 
the correct identification of target compounds and unknowns. 18 
In the present study, we established a recommendable procedure for 19 
analyzing five barbiturates (phenobarbital, cyclobarbital, amobarbital, 20 
secobarbital, thiopental) from human plasma samples and the metabolite of 21 
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amobarbital from human urine using the Monolithic C18 Spin Tip and 1 
UPLC-Q-ToF-MS analysis. This is the first report on use Monolithic C18 2 
Spin Tip for the extraction of barbituric acid drugs from human body fluids. 3 
 4 
 5 
Materials and methods 6 
 7 
Materials 8 
Amobarbital was provided by Nippon Shinyaku Co. Ltd. (Kyoto, Japan). 9 
Cyclobarbital was purchased from Tokyo Kasei Industry Co. Ltd. (Tokyo, 10 
Japan). Phenobarbital, secobarbital, thiopental, and 5-(4-methylphenyl)-5-11 
phenylhydantoin (internal standard, IS) was purchased from Sigma-Aldrich 12 
(St. Louis, MO). HPLC-MS grade acetonitrile was obtained from Wako 13 
Pure Chemical Industries Ltd. (Osaka, Japan). Other common chemicals 14 
used were of the highest purity commercially available. Ultra-pure water 15 
from the Milli-Q ultra-pure system (Komatsu Electronics Co., Ltd., 16 
Ishikawa, Japan) was used in all experiments. Monolithic C18 Spin Tips 17 
(C18-bonded monolithic silica gel with a diameter of 2.8 mm, thickness of 1 18 
mm, weight of 2.5 mg, mesopore size of 10 nm, through pore size of 5 µm, 19 
and surface area of 350 m2/g) were purchased from GL Sciences.  20 
 21 
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Preparation of plasma samples 1 
Drug-free whole blood samples from healthy volunteers, who were 2 
recruited among laboratory personnel, were obtained intravenously in the 3 
presence of heparin sodium as an anticoagulant. To prepare drug-free 4 
plasma samples, heparinized whole blood was centrifuged at 1700 × g for 5 
10 min at 4°C, and the plasma was decanted into a clean centrifuge tube. 6 
The drug-free plasma samples were stored at −80°C until use. 7 
 8 
Preparation of standard solutions and quality control samples 9 
Individual stock standard solutions (1 mg/ml) of the five barbiturates and 10 
the IS were prepared separately by dissolving an accurately weighed 11 
quantity of each drug in methanol. The solutions were then stored at 4°C. 12 
Working standard solutions of these drugs were prepared by appropriate 13 
dilution of the stock standard solutions using the HPLC mobile phase (10 14 
mM ammonium acetate in 50% acetonitrile). All working standard 15 
solutions were freshly prepared every week and stored at 4°C. Calibration 16 
standards were prepared by mixing appropriate amounts of the working 17 
standard solutions and drug-free plasma to achieve seven different 18 
concentrations ranging from 5 to 500 ng/20 µl (5, 10, 25, 50, 100, 250, and 19 
500 ng/20 µl) for five barbiturates, and 100 ng/20 µl for the IS. Quality 20 
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control (QC) samples (10–500 ng/20 µl) for all test drugs were also 1 
prepared using the same procedure. 2 
 3 
Extraction procedure using Monolithic C18 Spin Tip 4 
Extraction of five barbiturates and IS from human plasma and urine 5 
were achieved using a Monolithic C18 Spin Tip. Monolithic C18 Spin Tips 6 
were conditioned with 100 µl methanol and centrifuged at 1000 × g for 15 s, 7 
followed by 100 µl of ultra-pure water at 1000 × g for 15 s. For new tips, 8 
this procedure was repeated to reduce the background noise. To 20 µl of a 9 
human plasma sample containing 10 µl of drug mixture (five barbiturates 10 
and IS), 10 µl of 1 N HCl solution and 160 µl of ultra-pure water were 11 
added. For human urine samples of 100 µl of urine containing 10 µl of drug 12 
mixture (five barbiturates and IS), 10 µl of 1 N HCl solution and 80 µl of 13 
ultra-pure water were added. The sample solution was applied to the 14 
conditioned Monolithic C18 Spin Tip. The spin tip was centrifuged at 1000 15 
× g for 15 s. The spin tip was then washed with 100 µl of ultra-pure water 16 
at 1000 × g for 15 s. After washing, the analytes were eluted from the spin 17 
tip with 50 µl of methanol at 1000 × g for 10 s. A 5-µl aliquot of the eluate 18 
was directly analyzed by UPLC-Q-ToF-MS. 19 
 20 
UPLC-Q-ToF-MS conditions  21 
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A UPLC-Q-ToF-MS system consisting of an Acquity UPLC liquid 1 
chromatograph (Waters, Milford, MA, USA) and a Xevo G2 Q-TOF mass 2 
spectrometer (Waters, Milford, MA, USA) was used for all measurements. 3 
The Waters Acquity UPLC system was equipped with a binary solvent 4 
manager, sample manager, and column oven. The chromatographic 5 
separation of the five barbiturates and IS was achieved on a Waters 6 
Acquity UPLC BEH C18 column (50 mm × 2.1 mm., particle size 17-μm) 7 
with a linear gradient elution system composed of 10 mM ammonium 8 
acetate (pH 6.8) and methanol at a flow rate of 0.4 ml/min. Solvent A was 9 
ultra-pure water containing 10 mM ammonium acetate, and solvent B was 10 
methanol. Gradient runs were programmed to change from 90% solvent 11 
A/10% solvent B to 50% solvent A/50% solvent B within 2.5 min, and then 12 
to 1% solvent A/99% solvent B within 2.5 min. The column was 13 
subsequently maintained with 1% solvent A/99% solvent B for 1.0 min and 14 
then re-equilibrated with 90% solvent A/10% solvent B for 2.0 min before 15 
the next injection. The total chromatographic run time was 8 min. 16 
For confirmation, mass spectrometric measurements were performed 17 
using a Xevo G2 Q-TOF mass spectrometer. The analyses were carried out 18 
using the ESI setting in the negative mode (ESI−). The mass spectrometer 19 
was operated in negative ionization mode, with a capillary voltage of 2.8 20 
kV and a cone voltage of 30 V. The source and desolvation temperatures 21 
10 
 
were 150°C and 500°C, respectively. The desolvation gas flow was 1000 1 
l/hr and the cone gas flow 50 l/hr (both N2). The mass range considered 2 
was 100−1000 Da. Data were collected in centroid mode, and the 3 
sensitivity analyzer mode was selected. The accuracy and reproducibility of 4 
all the analyses were guaranteed by the use of a LockSpray. Leucine-5 
enkephalin was used as the lock mass at a concentration of 1 ng/ml in 50% 6 
of ultra-pure water-acetonitrile with 0.1% formic acid and a flow rate of 5 7 
μl/min. MassLynx version 4.1 (Waters, Milford, MA, USA) was used to 8 
analyze the samples. The parameter settings were as follows: the analysis 9 
time was 0–6 min; the spectrum was above the relative intensity of 2%; the 10 
maximum tolerance of mass error was set as 5 ppm. The prediction rules of 11 
elemental composition (EC) were defined as follows: atom numbers of 12 
carbon, hydrogen, oxygen, nitrogen, and sulfur were set to ranges of 0–100, 13 
0–200, 0–20, 0–20, and 0–6, respectively. The molecular formula 14 
assignments were obtained with the MassLynx i-Fit algorithm. For 15 
barbiturates and IS, the search was restricted to molecules containing 16 
CHONS only and the best Fit was obtained on both mass accuracy and 17 
isotope intensity pattern (i-Fit). Blank human plasma or urine samples were 18 
used as controls for comparison with the analytic samples, and all were 19 
processed under the same conditions. 20 
 21 
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Methods validation 1 
The method was validated for linearity, selectivity, precision, accuracy, 2 
and recovery according to the US Food and Drug Administration 3 
guidelines for bioanalytical method validation [22]. Regression equations 4 
of the barbiturates were obtained by plotting the peak-area ratio of 5 
analytes/IS (y-axis) against the analyte concentration (x-axis). The slope 6 
and y-intercept of the regression line were estimated in duplicate for each 7 
of ten different calibrations and on six consecutive days. The acceptance 8 
criterion for the correlation coefficient was > 0.998. The limit of detection 9 
(LOD) was defined as the lowest concentration of analyte spiked in plasma 10 
that could be detected with a signal-to-noise ratio of at least 3. The lower 11 
limit of quantification (LLOQ) was defined as the lowest concentration on 12 
the calibration curve that could be measured with a signal-to-noise ratio of 13 
at least 10.  14 
The selectivity of the method was estimated by analyzing blank human 15 
plasma matrix samples. The responses of the interfering substances or 16 
background noises at the retention time of barbiturates and IS were 17 
acceptable if they were less than 5% of the mean response of the LLOQ. 18 
Intra-day precision and accuracy were carried out by analyzing QC samples 19 
spiked with the five barbiturates at three different concentrations (10, 100, 20 
and 500 ng/20 µl) in six replicate samples on the same day. The 21 
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concentration of analytes in the QC samples was calculated using the 1 
calibration curves. The precision was determined by calculating the 2 
coefficient of variation (CV), while the accuracy was expressed as a 3 
percentage of the mean of measured concentration against the nominal 4 
concentration. The evaluations of precision were based on previously 5 
published criteria [22]. The acceptance criterion for precision (percentage 6 
CV) was ≤15%. Recovery was calculated by comparing the 7 
chromatographic peak areas of the analyte in QC samples with those 8 
obtained by direct injection of analyte standards dissolved in 10 mM 9 
ammonium acetate, and determined at different concentration levels (10, 10 
100, and 500 ng/20 µl).  11 
 12 
Administration of amobarbital to healthy volunteer 13 
The present method was applied to real samples of human plasma to 14 
confirm its utility. A therapeutic dose of amobarbital (300 mg) was 15 
administered orally to a 40-year-old male volunteer (body weight, 73 kg). 16 
Informed consent was obtained from the subject. Whole blood samples 17 
were collected pre-dose (0 h) and 1.5 h after drug administration, and 18 
transferred to centrifuge tubes containing heparin sodium. The heparinized 19 
blood samples were centrifuged at 1700 × g for 10 min at 4 °C and plasma 20 
13 
 
samples were stored at −80 °C until analysis. This study was approved by 1 
the Ethics Committee of Showa University School of Medicine (No 860). 2 
 3 
 4 
Results 5 
 6 
The exracted ion chromatogram (XIC) chromatograms and mass 7 
spectral data for the five barbiturates and IS obtained by UPLC-Q-ToF-MS 8 
using an ESI are shown in Fig. 2 and Table 1. Phenobarbital, cyclobarbital, 9 
amobarbital, secobarbital, thiopental, and the IS detected in negative-ion 10 
mode gave the deprotonated molecule [M-H]− at m/z 231.0765, 235.1076, 11 
225.1231, 2371232, 241.1006, and 265.0970, respectively, in the full-scan 12 
mode. These deprotonated molecules were identified as C12H11N2O3 (−2.2 13 
ppm mass error, 0.020 i-Fit) for phenobarbital, C12H15N2O3 (−3.0 ppm 14 
mass error, 0.015 i-Fit) for cyclobarbital, C11H17N2O3 (−3.6 ppm mass error, 15 
0.093 i-Fit) for amobarbital, C12H17N2O3 (−3.0 ppm mass error, 0.010 i-Fit) 16 
for secobarbital, C11H17N2O2S (−2.1 ppm mass error, 0.461 i-Fit) for 17 
thiopental, and C16H13N2O2 (−1.6 ppm mass error, 0.017 i-Fit) for IS, 18 
respectively. 19 
The regression equations of the five barbiturates showed good linearity 20 
from 5 to 500 ng/20 µl with correlation coefficients of at least 0.9984 21 
14 
 
(Table 2). The LOD and LLOQ of the barbiturates under optimal 1 
conditions were 1 ng/20 µl and 5 ng/20 µl for plasma, respectively (Table 2 
2). Intra-day precisions and accuracies were evaluated by assessing QC 3 
samples prepared from human plasma (Table 3). The intra-day CVs were 4 
no greater than 7.8%, and the accuracies ranged from 86.3% to 97.9% for 5 
all concentrations. The recoveries of the five barbiturates from human 6 
plasma samples determined at three different concentrations ranged within 7 
89.6–97.1% (Table 4). 8 
In addition to analysis of spiked human plasma, the present method was 9 
applied to human plasma and urine samples collected following oral 10 
administration of amobarbital (300 mg) to a male volunteer. The amount of 11 
the IS was 100 ng/20 µl for plasma and 100 ng/100 µl for urine, 12 
respectively. Figure 3 shows UPLC-Q-ToF-MS XICs chromatograms and 13 
typical spectra of EC of human plasma 1.5 h after oral administration. The 14 
drug concentration in plasma calculated by internal calibration was 44.1 15 
ng/20 µl 1.5 h after administration of amobarbital. The amobarbital and its 16 
hydroxide metabolite were identified using the present method from human 17 
urine 8 h after oral administration (Fig. 4). The deprotonated molecule was 18 
assigned as C11H17N2O4 (−2.5 ppm mass error, 0.354 i-Fit) for 3-19 
hydroxyamobarbital (Fig. 4).  20 
 21 
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 1 
Discussion 2 
 3 
Optimization of extraction conditions for Monolithic C18 Spin Tip 4 
The entire Monolithic C18 Spin Tips extraction process, including 5 
conditioning, sample loading, washing, and elution required approximately 6 
2 min. In contrast, the time required to manually perform conventional 7 
cartridge SPE was reported to be >20 min [23–26]. The eluate from the 8 
Monolithic C18 Spin Tips was directly injected into the UPLC-Q-ToF-MS 9 
without evaporation and reconstitution steps, which is particularly 10 
important for rapid and simple analysis. Therefore, the use of Monolithic 11 
C18 Spin Tips is recommended for rapid extraction of barbiturates and its 12 
metabolites from human body fluids. The total solvent volume used for 13 
each step of the extraction process was 500 µl, which is lower than 14 
volumes required by conventional SPE cartridges (around 5.6–65 ml) 15 
[23−26]. Furthermore, the required plasma or urine sample volume was 16 
reduced to 20 or 100 µl, respectively, which corresponds to 4.5–50 times 17 
less than volumes previously reported for barbiturates analysis in plasma 18 
and urine samples [23−26]. Thus, the small volumes of solvent and samples 19 
needed with the method used in this study represent a significant advance 20 
in sample preparation miniaturization and the overall procedure can be 21 
16 
 
considered to be “green” because it requires little solvent and produces 1 
little waste. 2 
 3 
Method performance 4 
Figure 2 shows TIC and XIC chromatograms obtained by UPLC-Q-ToF-5 
MS for barbiturate drugs from human plasma containing the test 6 
compounds (50 ng per 20 µl). Distinct peaks appeared for each drug and 7 
the IS on the chromatograms within 4 min. Blank chromatograms gave 8 
small impurity peaks and no interfering peaks appeared around the 9 
retention times of the test compounds (data not shown). The spectra 10 
obtained showed the accurate corresponding masses for the deprotonated 11 
molecular ions. The criteria of the potential candidate ions used for EC 12 
analysis included mass error (mDa and ppm), double bond equivalent 13 
(DBE, total number of rings and double bonds in a molecule), empirical 14 
formula, and i-Fit value (the likelihood that the isotopic pattern of the EC 15 
matches a cluster of peaks in the spectrum). The potential calculated 16 
masses, mass accuracy, DBE, i-Fit value, and ECs associated with the 17 
measured mass of the marker ion were generated and analyzed with the 18 
ChemSpider and SciFinder libraries. The lower i-Fit value and the better 19 
the Fit Conf for barbiturates and IS were obtained (Table 1). 20 
17 
 
The present method showed good linearity for the known components 1 
tested, with LOD and LLOQ for human plasma under optimal conditions 2 
corresponding to 1 ng/20 µl and 5 ng/20 µl, respectively. Furthermore, 3 
lower i-Fit value was obtained under LLOQ concentration (Table 2). With 4 
therapeutic levels in plasma or serum of barbiturates reported to be 5 
10000−40000 ng/ml for phenobarbital [27], 2000−6000 ng/ml for 6 
cyclobarbital [28], 2500−4000 ng/ml for amobarbital [29], 1000−2200 7 
ng/ml for secobarbital [30], and 25000–50000 ng/ml for thiopental [31], the 8 
present method is sensitive enough to analyze these drugs at therapeutic 9 
levels.  10 
The intra-day CVs at three concentrations examined were below 7.8%, 11 
and the accuracies ranged from 86.3% to 97.9% for all concentrations 12 
(Table 3), leading us to consider this variability acceptable for method 13 
validation based on current criteria [32, 33]. The recoveries of the five 14 
barbiturates from human plasma samples determined at three different 15 
concentrations ranged within 89.6–97.1% (Table 4). The reduced recovery 16 
(below 100%) is probably due to a loss of analyte during overall sample 17 
preparation steps. However, the reduction was not problematic, because 18 
satisfactory quantification was achieved using the method described, as 19 
shown in Table 2 and 3. 20 
 21 
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Actual measurements of amobarbital in human plasma after oral 1 
administration 2 
In addition to analysis of spiked human plasma, the present method was 3 
applied to human plasma samples collected following oral administration 4 
of amobarbital to a male volunteer. Typical XIC chromatograms from this 5 
analysis are shown in Fig. 3. The drug concentration in plasma calculated 6 
by internal calibration was 44.1 ng/20 µl 1.5 h after administration of 7 
amobarbital. This concentration was within therapeutic levels and UPLC-8 
Q-ToF-MS analysis [29].  9 
 10 
 11 
Conclusions 12 
 13 
We have established a detailed procedure for the quantitative 14 
determination and identification of barbiturates and a metabolite in human 15 
body samples via a novel Monolithic C18 Spin Tip and UPLC-Q-ToF-MS 16 
analysis. The use of Monolithic C18 Spin Tips represents an ideal sample 17 
preparation technique because of the simple extraction, and minimal 18 
sample and solvent requirements. The recoveries of the five drugs in 19 
plasma were 86−98% and the LLOQ was 5 ng/20 µl. The intra-day CVs for 20 
all the drugs in plasma were less than 7.8%. This method will be useful for 21 
19 
 
high-throughput determination of barbiturates in clinical and toxicological 1 
analyses. We are currently developing this technique for the detection of 2 
other classes of drugs in human body fluid samples. 3 
 4 
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Figure captions 1 
 2 
Fig. 1. Appearance of a Monolithic C18 gel-packed Spin Tip and electron 3 
micrograph of the monolithic silica gel. 4 
 5 
Fig. 2. TIC and XIC chromatograms of UPLC-Q-TOF-MS for barbiturate 6 
drugs from human plasma in negative ESI mode. The mixture of drugs (50 7 
ng each) and 5-(4-methylphenyl)-5-phenylhydantoin used as IS (100 ng) 8 
were spiked into 20 µl of plasma. The MS spectra of XIC chromatograms 9 
are consistent with those reported in Table 1. 10 
 11 
Fig. 3. UPLC-Q-Tof-MS XICs chromatograms and spectra of elemental 12 
composition from human plasma 1.5 h after oral administration of 13 
amobarbital (300 mg). The amount 5-(4-methylphenyl)-5-phenylhydantoin 14 
used as IS was 100 ng/20 µl of plasma. 15 
 16 
Fig. 4. UPLC-Q-Tof-MS XICs chromatograms and spectra of elemental 17 
composition from human urine 8 h after oral administration of amobarbital 18 
(300 mg). The amount 5-(4-methylphenyl)-5-phenylhydantoin used as IS 19 
was 100 ng/100 µl of urine. 20 
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